Metacrine Valuation
| MTCRDelisted Stock | USD 0.49 0.00 0.00% |
Metacrine is overvalued. Metacrine secures a last-minute Real Value of $0.41 per share. The latest price of the firm is $0.49. Our model forecasts the value of Metacrine from analyzing the firm fundamentals such as Return On Equity of -0.91, shares owned by insiders of 12.29 %, and Current Valuation of (23.98 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Metacrine's price fluctuation is very steady at this time. Calculation of the real value of Metacrine is based on 3 months time horizon. Increasing Metacrine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Metacrine stock is determined by what a typical buyer is willing to pay for full or partial control of Metacrine. Since Metacrine is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Metacrine Stock. However, Metacrine's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.49 | Real 0.41 | Hype 0.49 |
The intrinsic value of Metacrine's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Metacrine's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Metacrine helps investors to forecast how Metacrine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Metacrine more accurately as focusing exclusively on Metacrine's fundamentals will not take into account other important factors: Metacrine Total Value Analysis
Metacrine is now forecasted to have valuation of (23.98 M) with market capitalization of 20.94 M, debt of 13.3 M, and cash on hands of 55.53 M. The negative valuation of Metacrine may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Metacrine fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(23.98 M) | 20.94 M | 13.3 M | 55.53 M |
Metacrine Asset Utilization
One of the ways to look at asset utilization of Metacrine is to check how much profit was generated for every dollar of assets it reports. Metacrine secures a negative usage of assets of -0.37 %, losing $0.003686 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Metacrine shows how discouraging it operates for each dollar spent on its assets.Metacrine Ownership Allocation
Metacrine maintains a total of 42.57 Million outstanding shares. 30% of Metacrine outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Metacrine Profitability Analysis
Net Loss for the year was (62.21 M) with loss before overhead, payroll, taxes, and interest of (45.47 M).About Metacrine Valuation
The delisted stock valuation mechanism determines Metacrine's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Metacrine based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Metacrine. We calculate exposure to Metacrine's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Metacrine's related companies.Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Metacrine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Metacrine Growth Indicators
Investing in growth stocks can be very risky. If the company such as Metacrine does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 26 M | |
| Retained Earnings | -183 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Metacrine Stock
If you are still planning to invest in Metacrine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metacrine's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |